Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
(Thomson Reuters ONE) -
WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of therapies to treat central nervous system (CNS) disorders, today
announced the appointment of Michael Davidson, M.D., as chief medical officer
effective December 19, 2016. His responsibilities will include the strategic
development and clinical advancement of the Company's products, which target
schizophrenia (MIN-101), insomnia (MIN-202), major depressive disorder (MIN-
117) and Parkinson's disease (MIN-301).
Dr. Davidson brings to Minerva significant experience in the research and
development of drugs to treat diseases of the central nervous system. He is
currently professor of psychiatry at the Sackler School of Medicine, Tel Aviv
University. Dr. Davidson trained in psychiatry at the Mount Sinai School of
Medicine in New York, where he served as professor of psychiatry and director of
research.
"Dr. Davidson's deep expertise in CNS disorders, his insights into the
development strategy and regulatory review of new agents to treat these
conditions and his broad knowledge of clinical operations are expected to help
us realize the potential of Minerva's portfolio of products to treat unmet
medical needs," said Dr. Remy Luthringer, president and chief executive officer
of Minerva. "During the past year, we have benefitted from his capabilities as
a consultant, and we are looking forward to his increased involvement as we
interact with regulatory agencies in the U.S. and Europe and as we embark upon
pivotal clinical testing with our lead product, MIN-101 for schizophrenia."
Dr. Davidson has been a consultant for a number of pharmaceutical and
biotechnology companies, including Pfizer, Johnson and Johnson, Teva, Roche,
Novartis, Lilly, Forest, BioLineRx, Sanofi-Aventis, Takeda, Orion and Servier.
He is a board member and reviewer for several professional organizations and
neuroscience and psychiatry publications. Dr. Davidson has served as chief
editor of European Neuropsychopharmacology, fellow of the American College of
Neuropsychopharmacology and board member of the International Psychogeriatric
Association. He received the Neuroscience Award from the European College of
Neuropsychopharmacology in 1999 and from the International College of
Neuropsychopharmacology in 2006. Dr. Davidson is the recipient of over 50
research grants and has published over 300 articles primarily in peer reviewed
journals in the areas of schizophrenia and Alzheimer's disease. In schizophrenia
he has generated and published data focused on the underlying biology of the
disease and on investigational treatments.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, which has
completed a Phase IIb clinical trial for schizophrenia; MIN-117, which has
completed a Phase IIa clinical trial development for MDD; MIN-202 (JNJ-
42847922), which has completed Phase IIa and Phase Ib clinical trials for
insomnia and MDD, respectively; and MIN-301, in pre-clinical development for
Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global
Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical
facts, reflect management's expectations as of the date of this press release,
and involve certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the timing and results of future clinical
milestones with MIN-101, MIN-117, MIN-202 and MIN-301; the clinical and
therapeutic potential of MIN-101, MIN-117, MIN-202 and MIN-301; our ability to
successfully develop and commercialize MIN-101, MIN-117, MIN-202 and MIN-301;
and management's ability to successfully achieve its goals. These forward-
looking statements are based on our current expectations and may differ
materially from actual results due to a variety of factors including, without
limitation, whether MIN-101, MIN-117, MIN-202 and MIN-301 will advance further
in the clinical trials process and whether and when, if at all, they will
receive final approval from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies and for which indications; whether the results of
future clinical trials of MIN-101, MIN-117, MIN-202 and MIN-301, if any, will be
consistent with the results of past clinical trials; whether MIN-101, MIN-117,
MIN-202 and MIN-301 will be successfully marketed if approved; whether our
therapeutic product discovery and development efforts with MIN-101, MIN-117,
MIN-202 and MIN-301 will be successful; our ability to achieve the results
contemplated by our co-development agreements; management's ability to
successfully achieve its goals; our ability to raise additional capital to fund
our operations on terms acceptable to us; and general economic conditions.
These and other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully detailed under the
caption "Risk Factors" in our filings with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016, filed with the Securities and Exchange Commission on August
4, 2016. Copies of reports filed with the SEC are posted on our website
at www.minervaneurosciences.com. The forward-looking statements in this press
release are based on information available to us as of the date hereof, and we
disclaim any obligation to update any forward-looking statements, except as
required by law.
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
Datum: 20.12.2016 - 14:30 Uhr
Sprache: Deutsch
News-ID 514058
Anzahl Zeichen: 7166
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
